Ipsen's Stock Soars 3% After a 22.6% Increase in Q1 Revenue

Strong Quarterly Performance and Strategic Confirmations

This morning, Ipsen revealed a quarterly revenue of 1,074.9 million euros, growing by 22.6% at constant exchange rates. In reported data, the growth was 17.0%, a discrepancy reflecting an unfavorable exchange rate effect. All three therapeutic areas of the laboratory contributed to this acceleration. The management also reiterated its targets for fiscal year 2026, expecting an annual sales growth exceeding 13.0% at constant exchange rates and an operating margin over 35.0%. The stock also benefits from the momentum related to the conditional European authorization obtained the day before for Ojemda (tovorafenib), intended for the treatment of pediatric low-grade gliomas with a BRAF alteration. This green light, applicable in the 27 countries of the European Union as well as in Iceland, Liechtenstein, and Norway, expands the group's oncology portfolio. The next key date on the calendar is the general meeting scheduled for May 13.

Technical Analysis and Market Context

Graphically, the price of 164.90 euros is at 69% of the Bollinger band, located in the upper half of the channel defined by an upper bound of 171.54 euros and a lower bound of 150.43 euros, without indicating an excessive bullish trend. The stock is trading above its 50-day moving average (157.76 euros) and well beyond the 200-day MA at 129.19 euros, showing a solidly upward-oriented trend. The RSI, at 51, remains in a neutral zone, allowing room for progression before reaching an overbought territory. The market context supports this movement: the CAC 40 is up by 0.55% during the session, at 8201 points. Among comparable stocks, Sanofi is up by 3.32% while UCB gains 1.07%, in a generally buoyant European pharmaceutical sector this Thursday. The nearest resistance for Ipsen is at 169.70 euros, a level that, if breached, would open up additional technical space.